Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-04-04 Capital/Financing Update
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC under the Securities Act of 1933. It includes detailed information about indemnification of directors and officers, recent sales of unregistered securities, and exhibits related to the registration statement. The Form S-1 is a registration statement used for securities offerings, not a financial report or earnings release. It is a capital markets filing related to the company's fundraising and securities issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement. Hence, the classification is CAP with high confidence.
2022-04-04 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a formal correspondence related to the registration process of securities, not a financial report or detailed filing. The document is short (1527 characters) and does not contain financial data or detailed disclosures. It is essentially a regulatory communication about the status of a filing, not the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2022-03-31 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a correspondence related to a regulatory filing process, specifically about the registration statement effectiveness, not the registration statement itself or any financial report. The document is short (1515 characters) and is a formal request rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-03-31 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Titan Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the offering, selling stockholders, risk factors, and other information typical of a registration statement prospectus. This is not a financial report, earnings release, or management discussion, but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS.
2022-03-28 English
10-K
Annual Report FY 2021
2022-03-25 English
Regulatory Filings 2022
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, documents that do not fit any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of information.
2022-02-16 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.